↓ Skip to main content

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

Overview of attention for article published in Blood Cancer Discovery, April 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#34 of 206)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
4 news outlets
twitter
43 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Published in
Blood Cancer Discovery, April 2023
DOI 10.1158/2643-3230.bcd-22-0205
Pubmed ID
Authors

Curtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R Luskin, Dzifa Y Duose, Rebecca S S Tidwell, Nicholas J Short, Gautam Borthakur, Tapan M Kadia, Lucia Masarova, George D Tippett, Prithviraj Bose, Elias J Jabbour, Farhad Ravandi, Naval G Daver, Guillermo Garcia-Manero, Hagop Kantarjian, Jacqueline S Garcia, Paresh Vyas, Koichi Takahashi, Marina Konopleva, Courtney D DiNardo

X Demographics

X Demographics

The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 15%
Student > Postgraduate 2 10%
Researcher 2 10%
Student > Doctoral Student 1 5%
Student > Bachelor 1 5%
Other 2 10%
Unknown 9 45%
Readers by discipline Count As %
Medicine and Dentistry 4 20%
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Biochemistry, Genetics and Molecular Biology 2 10%
Immunology and Microbiology 1 5%
Unspecified 1 5%
Other 0 0%
Unknown 10 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 55. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2024.
All research outputs
#774,908
of 25,394,764 outputs
Outputs from Blood Cancer Discovery
#34
of 206 outputs
Outputs of similar age
#16,713
of 410,075 outputs
Outputs of similar age from Blood Cancer Discovery
#6
of 12 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 206 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.8. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 410,075 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.